Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co Goodwill

The Goodwill of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 24, 2026 is 18.70 M CNY. In the previous year, Goodwill was 19.22 M CNY — a change of -2.67% (lower).

Goodwill

18.70 MCNY

YoY

-2.67%

Last updated:

Goodwill of Tibet Duo Rui Pharmaceutical Co is 2025 18.70 M CNY. Goodwill of Tibet Duo Rui Pharmaceutical Co was 2024 19.22 M CNY. It decreases by -2.67% lower compared to the previous year.

The Tibet Duo Rui Pharmaceutical Co Goodwill history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Goodwill
Date
Goodwill
Jan 1, 2023
3.69 M CNY
Jan 1, 2024
19.22 M CNY
Jan 1, 2025
18.70 M CNY
The Tibet Duo Rui Pharmaceutical Co Goodwill history
YEARGoodwillYoY
18.70 MCNY-2.67%
19.22 MCNY+421.42%
3.69 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

Goodwill of Tibet Duo Rui Pharmaceutical Co is 18.70 M CNY in 2025.

Goodwill of Tibet Duo Rui Pharmaceutical Co changed from 19.22 M CNY to 18.70 M CNY, representing a -2.67% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Goodwill Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Tibet Duo Rui Pharmaceutical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tibet Duo Rui Pharmaceutical Co

All Key Metrics — Tibet Duo Rui Pharmaceutical Co